Mezim Pro, 20 pcs.

Pharmacotherapeutic group: Digestive enzyme agent

ATX code:A09AA02.

Pharmacological properties

Pharmacodynamics.

The enzyme drug that improves digestion. Pancreatin is a powder from porcine pancreatic glands, which contains other enzymes along with the external pancreatic enzymes – lipase, amylase, protease, trypsin and chymotrypsin.

The pancreatic enzymes in the drug facilitate the breakdown of proteins, fats and carbohydrates, which leads to their more complete absorption in the small intestine. Trypsin suppresses stimulated pancreatic secretion with analgesic effect. Maximum enzymatic activity of the drug is noted 30-45 min after oral administration.

Pharmacokinetics.

The tablets of Mesim® Pro are covered with an acid-proof coating which is insoluble under the action of gastric hydrochloric acid and by this means protects the enzymes contained in the drug from inactivation. Solution of the coating and release of enzymes occurs at pH values close to neutral or slightly alkaline.

Indications

replacement therapy for exocrine pancreatic insufficiency (including chronic pancreatitis, cystic fibrosis);
chronic inflammatory-dystrophic diseases of the stomach, intestines, liver, gall bladder;
conditions after resection or irradiation of the gastrointestinal tract, accompanied by impaired digestion of food, flatulence, diarrhea (as part of combination therapy);
gastrointestinal disorder of a functional nature (with intestinal infectious diseases, irritable bowel syndrome, etc.);
to improve food digestion in patients with normal gastrointestinal function in case of dietary errors;
preparation for x-ray and ultrasound examinations of the abdominal organs.

Pharmacological effect

Pharmacotherapeutic group: Digestive enzyme agent

ATX code: A09AA02.

Pharmacological properties

Pharmacodynamics.

An enzyme preparation that improves digestion. Pancreatin is a powder from pork pancreas, which, along with exocrine pancreatic enzymes – lipase, amylase, protease, trypsin and chymotrypsin, also contains other enzymes.

Pancreatic enzymes included in the drug facilitate the breakdown of proteins, fats and carbohydrates, which leads to their more complete absorption in the small intestine. Trypsin suppresses stimulated pancreatic secretion, producing an analgesic effect. The maximum enzymatic activity of the drug is observed 30-45 minutes after oral administration.

Pharmacokinetics.

Mezim ® Pro tablets are coated with an acid-resistant coating that does not dissolve under the action of hydrochloric acid of the stomach and thereby protects the enzymes contained in the drug from inactivation. Dissolution of the shell and release of enzymes occurs at a pH value close to neutral or slightly alkaline.

Special instructions

In case of acute pancreatitis or exacerbation of chronic pancreatitis (at the stage of attenuation of exacerbation), during a restorative diet, it is advisable to prescribe the drug Mezim ® Pro against the background of existing or remaining insufficiency of pancreatic function.

The drug Mezim ® Pro, taking into account the solid indivisible dosage form, is contraindicated in children under 3 years of age.

Effect of the drug on the ability to drive vehicles and machinery

The drug Mezim ® Pro does not affect the speed of psychomotor reactions and the ability to perceive or assess a situation.

Active ingredient

Pancreatin

Composition

Core

Active ingredient:

Pancreatin* 100,000 –138,889 mg with minimal activity:

lipase 10000 units
amylase 7500 units
protease 375 units

Excipients: lactose monohydrate, microcrystalline cellulose (type 12), colloidal silicon dioxide, crospovidone, magnesium stearate;

Shell: hypromellose (~5 mPa s), methacrylic acid and ethyl acrylate copolymer (1:1) dispersion 30% (dry weight), triethyl citrate, titanium dioxide (E 171), talc, simethicone emulsion 30% (dry weight), macrogol 6000, sodium carmellose, polysorbate 80, azorubine varnish (E 122), sodium hydroxide.

*obtained from pork pancreas

Contraindications

acute pancreatitis;
exacerbation of chronic pancreatitis;
hypersensitivity to pancreatin or other components of the drug;
hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome;
children under 3 years of age (indivisible dosage form).

Side Effects

No side effects or complications were detected even with long-term and regular use of the drug Mezim ® Pro in patients with impaired pancreatic function.

In some cases, after taking pancreatin, allergic reactions may develop, rarely – diarrhea or constipation, nausea, discomfort. epigastric region. In isolated cases, in patients suffering from cystic fibrosis, with prolonged use of high doses of the drug, hyperuricosuria (increased levels of uric acid in the blood plasma) may develop, and strictures may form in the ileocecal region and ascending colon.

Interaction

When taking medications containing pancreatin, the absorption of folic acid may be reduced. The effect of hypoglycemic drugs (acarbose, miglitol) may decrease when taken simultaneously with pancreatin.

With the simultaneous use of pancreatin with iron preparations, the absorption of the latter may be reduced. The simultaneous use of antacids containing calcium carbonate and/or magnesium hydroxide may lead to a decrease in the effectiveness of the drug.

Overdose

There are no data on cases of overdose and intoxication with the drug.
Possible: hyperuricosuria, hyperuricemia, in children – constipation.
Treatment: drug withdrawal, symptomatic therapy.

Storage conditions

At a temperature not higher than 25 oC.
Keep the medicine out of the reach of children!

Shelf life

3 years.
Do not use after expiration date.

Organization receiving complaints from consumers:

LLC “Berlin-Chemie/A. Menarini”, Russia

123112, Moscow, Presnenskaya embankment, building 10, Business Center “Tower on the Embankment”, Block B, tel. (495) 785-01-00, fax (495) 785-01-01.

Manufacturer

Berlin-Chemie AG, Germany